Free Trial
NASDAQ:CPIX

Cumberland Pharmaceuticals (CPIX) Stock Price, News & Analysis

Cumberland Pharmaceuticals logo
$5.34 +0.26 (+5.12%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$5.16 -0.18 (-3.45%)
As of 05/27/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cumberland Pharmaceuticals Stock (NASDAQ:CPIX)

Key Stats

Today's Range
$5.16
$5.40
50-Day Range
$3.91
$5.56
52-Week Range
$1.04
$7.25
Volume
36,953 shs
Average Volume
861,361 shs
Market Capitalization
$79.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Cumberland Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
14th Percentile Overall Score

CPIX MarketRank™: 

Cumberland Pharmaceuticals scored higher than 14% of companies evaluated by MarketBeat, and ranked 885th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Cumberland Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cumberland Pharmaceuticals is -6.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cumberland Pharmaceuticals is -6.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cumberland Pharmaceuticals has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cumberland Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.11% of the float of Cumberland Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cumberland Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cumberland Pharmaceuticals has recently decreased by 39.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cumberland Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Cumberland Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.11% of the float of Cumberland Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cumberland Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cumberland Pharmaceuticals has recently decreased by 39.04%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cumberland Pharmaceuticals has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Cumberland Pharmaceuticals this week, compared to 9 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cumberland Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    44.85% of the stock of Cumberland Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.51% of the stock of Cumberland Pharmaceuticals is held by institutions.

  • Read more about Cumberland Pharmaceuticals' insider trading history.
Receive CPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPIX Stock News Headlines

Trump Quietly Planning $15 Trillion Crypto Shocker
Most investors are still unaware, but I believe a new White House action may have quietly opened the floodgates for a $15 trillion crypto surge. My latest crypto playbook reveals the coin I’m most bullish on—including the name, ticker, and why I’m investing personal capital into it.
See More Headlines

CPIX Stock Analysis - Frequently Asked Questions

Cumberland Pharmaceuticals' stock was trading at $2.37 at the start of the year. Since then, CPIX stock has increased by 125.3% and is now trading at $5.34.
View the best growth stocks for 2025 here
.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released its earnings results on Tuesday, May, 6th. The specialty pharmaceutical company reported $0.15 earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative trailing twelve-month return on equity of 9.50%.
Read the conference call transcript
.

Top institutional shareholders of Cumberland Pharmaceuticals include Berkshire Asset Management LLC PA (1.10%), Adage Capital Partners GP L.L.C. (1.07%), Bank of New York Mellon Corp (0.52%) and Informed Momentum Co LLC (0.51%). Insiders that own company stock include Kenneth Krogulski, James Jones and Caroline Young.
View institutional ownership trends
.

Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cumberland Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Exxon Mobil (XOM), Netflix (NFLX) and Intel (INTC).

Company Calendar

Last Earnings
5/06/2025
Today
5/27/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CPIX
Employees
80
Year Founded
1999

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,280,000.00
Pretax Margin
-29.32%

Debt

Sales & Book Value

Annual Sales
$41.08 million
Cash Flow
$0.62 per share
Price / Cash Flow
8.61
Book Value
$1.96 per share
Price / Book
2.72

Miscellaneous

Free Float
7,962,000
Market Cap
$79.89 million
Optionable
Optionable
Beta
-0.35

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:CPIX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners